Evidence map›Paper›PMID 40340441›Full record

ArticleJournal of comparative effectiveness research2025

Overall survival in patients with metastatic castration-sensitive prostate cancer treated with apalutamide versus abiraterone acetate: a head-to-head analysis of real-world patients in the USA.

Benjamin Lowentritt, Mehmet A Bilen, Ibrahim Khilfeh, Carmine Rossi, Shawn Du, Frederic Kinkead, Lilian Diaz, Dominic Pilon, Lorie Ellis, Neal D Shore

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of comparative effectiveness research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Benjamin LowentrittChesapeake Urology, Towson, MD 21204, USA.
Mehmet A BilenWinship Cancer Institute of Emory University, Atlanta, GA 30322, USA.
Ibrahim KhilfehJohnson & Johnson, Horsham, PA 19044, USA.
Carmine RossiAnalysis Group, Inc., Montréal, QC H3B 0G7, Canada.
Shawn DuJohnson & Johnson, Horsham, PA 19044, USA.
Frederic KinkeadAnalysis Group, Inc., Montréal, QC H3B 0G7, Canada.
Lilian DiazAnalysis Group, Inc., Montréal, QC H3B 0G7, Canada.
Dominic PilonAnalysis Group, Inc., Montréal, QC H3B 0G7, Canada.
Lorie EllisJohnson & Johnson, Horsham, PA 19044, USA.
Neal D ShoreCarolina Urologic Research Center, Myrtle Beach, SC 29572, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Abiraterone AcetateAndrogen Receptor AntagonistsProstatic Neoplasms, Castration-ResistantThiohydantoinsAgedAged, 80 and overHumansMaleMiddle AgedNeoplasm MetastasisRetrospective StudiesUnited StatesAbiraterone AcetateAndrogen Receptor AntagonistsapalutamideThiohydantoinsandrogen receptor pathway inhibitorscomparative effectiveness researchprostatic neoplasms

Identifiers

PMID40340441
PMCPMC12224120

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.